Zentalis Pharmaceuticals Announces Positive Initial Clinical Data on ZN-c3, its Wee1 Inhibitor, in Patients with Advanced Ovarian Cancer at AACR
Retrieved on:
Friday, April 8, 2022
Company, Private Securities Litigation Reform Act, Vomiting, Drug development, Cancer, Abstract, Population, Therapy, DDI, Interim, PARP, University of Oklahoma College of Medicine, DNA, Investor, AML, Cell death, DNA repair, Selective estrogen receptor degrader, SEC, EDT, Standard of care, Associate, Failure, Nausea, NSCLC, Osteosarcoma, EGFR, Ovarian cancer, MD, Neutropenia, Thrombocytopenia, Anemia, Safety, Biology, U.S. Securities and Exchange Commission, Western Airlines Flight 2605, CDK, Jim, COVID-19, SERD, Large-cell lung carcinoma, Gynecologic Oncology (journal), FDA, Breast cancer, Annual report, University, Patient, Toxicity, Pharmaceutical industry, Aluminium, USC, Wee1
Wee1 inhibition remains a promising therapeutic approach to treating an array of solid tumors, including advanced ovarian cancer, and these results further support the class potential in changing the treatment paradigm.
Key Points:
- Wee1 inhibition remains a promising therapeutic approach to treating an array of solid tumors, including advanced ovarian cancer, and these results further support the class potential in changing the treatment paradigm.
- Interim data from the Phase 1 monotherapy USC expansion cohort receiving ZN-c3 300mg QD were also released today.
- ZN-c3 is potentially a best-in-class Wee1 inhibitor and is in an ongoing potentially registrational Phase 2 trial for USC patients (NCT04814108).
- Zentalis plans to initiate a combination study of ZN-c5 + ZN-c3 in ER+/HER2- CDK 4/6i-resistant breast cancer patients in 2022.